

Sample ID: **ACTN01029999T** | Gender: **Male** | Birth year: **1950** | WHO: **1**

Tumor: **Skin - Melanoma** | Stage: **IV**

## Summary

### Patient clinical history (31-Jan-2022)

Relevant systemic treatment history	<b>Vemurafenib (2/2021), Ipilimumab (2022)</b>
Other oncological history	<b>Resection (2020)</b>
	<b>Previous primary tumor: Bone/Soft tissue Schwannoma (2/2019, considered active)</b>
Relevant non-oncological history	<b>Pancreatitis, Myocardial infarction</b>

### Tumor details (31-Jan-2022)

Biopsy location	<b>Liver</b>
Lesion locations	<b>CNS (active, not symptomatic), Liver, Pulmonal, Abdominal</b>
Measurable disease (RECIST)	<b>Yes</b>

### Molecular results (WGS, 05-Feb-2022)

Molecular results have reliable quality	<b>Yes</b>
Events with approved treatment evidence in CKB	<b>BRAF V600E, High TML</b>
Events with trial eligibility in ACTIN database	<b>BRAF V600E, High TML</b>
Additional events with experimental evidence in CKB	<b>None</b>
Additional events with other responsive evidence in CKB	<b>None</b>
Events with resistance evidence in CKB	<b>BRAF V600E: Erlotinib</b>

### Trials and cohorts considered potentially eligible (2)

Trial ID	Acronym	Cohort	Cohort open?
Test Trial	TEST-TRIAL	Cohort B	<b>Yes</b>
Test Trial	TEST-TRIAL	Cohort C	<b>Yes</b>

## Clinical Details

### Patient current details (31-Jan-2022)

Unresolved toxicities grade => 2	<b>Fatigue (2), Dizziness</b>
Significant aberration on latest ECG	<b>Atrial arrhythmia</b>
Cancer-related complications	<b>Ascites</b>

### Laboratory results (31-Jan-2022)

Liver function	Total bilirubin		
	ASAT	(< 33 U/l)	<b>36 U/l (no trend information available)</b>
	ALAT		
	ALP		
	Albumin		
Kidney function	Creatinine		
	CKD-EPI eGFR	(> 100 mL/min)	<b>&gt; 100 mL/min (11-Jan-2022)</b>
Other	Hemoglobin	(6.5 - 9.5 mmol/L)	<b>5.5 mmol/L (no trend information available)</b>
	Thrombocytes	(155 - 350 10*9/L)	<b>150 10*9/L (out of range for 2 cons. measurements, trend down)</b>
	LDH	(< 245 U/L)	<b>240 U/L (21-Jan-2022)</b>

## Trial Matching Summary

### Trial counts

Trials evaluated	1
Cohorts evaluated	3

### Evaluation results per trial & cohort

Trial / Cohort	# Criteria	# Pass	# Warn	# Fail	# Undet.	# No eval	# No imp
Test Trial (TEST-TRIAL)	3	2	0	0	0	1	0
Test Trial - Cohort A	1	0	0	1	0	0	0
Test Trial - Cohort B	0	0	0	0	0	0	0
Test Trial - Cohort C	0	0	0	0	0	0	0

## Trial Matching Details

### Potentially eligible trials & cohorts

#### Test Trial

Evaluation **PASS**  
Acronym **TEST-TRIAL**  
Title **This is an ACTIN test trial**

Rule	Reference	Evaluation
E-01	This rule has 2 conditions: 1. Patient has no symptomatic CNS metastases. 2. Patient has exhausted SOC.	NOT_EVALUATED
I-01	Is adult	PASS
E-01	This rule has 2 conditions: 1. Patient has no symptomatic CNS metastases. 2. Patient has exhausted SOC.	PASS

#### Test Trial - Cohort A

Cohort ID **A**  
Evaluation **FAIL**  
Open for inclusion? **Yes**

Rule	Reference	Evaluation
I-02	Has no active CNS metastases	FAIL

#### Test Trial - Cohort B

Cohort ID **B**  
Evaluation **PASS**  
Open for inclusion? **Yes**

#### Test Trial - Cohort C

Cohort ID **C**  
Evaluation **PASS**  
Open for inclusion? **Yes**

